Bonesupport Holding Ab · OMXSTO:BONEX
Bonesupport Holding Ab — Q2 2020 Earnings Presentation
18 slides from Bonesupport Holding Ab's earnings presentation, Jul 17, 2020
Slide 1: BONESUPPORT Q2(20)
BONESUPPORT Q2(20) July 17th 2020 Emil Billbäck, CEO Håkan Johansson, CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: Financial and operational highlights Q2 2020
Financial highlights Q2 2020 • Net sales SEK 36 m, growth -3% • EU & ROW SEK 15 m, -35% YoY, with CERAMENT G & V -34% • North America SEK 22 m, +46% YoY • EBIT: SEK -24 m (SEK -48 m) Operational highlights Q2 2020 • SEK 378 m raised in May through direct share issue • DeNovo application for CERAMENT
Slide 4: COVID-19 – Impact on business and measures taken
COVID-19 – Impact on business and measures taken • Elective surgeries deferred to later date • Greatest impact in countries with high incidence of infected and imposed restrictions. Higher impact on university hospitals versus regional/ local hospitals • Number of trauma cases influenced by stay-at-
Slide 5: Strong US performance in Q2 2020 despite COVID-19 pandemic
Strong US performance in Q2 2020 despite the influence by the COVID-19 pandemic LTM Quarterly Sales per Segment US distribution with 40 independent • Historical distribution distributors (dark blue bar) 180 166 18.0 partner in US addressed 165 155 30% of potential market. 160 16.0 US distribution wi
Slide 6: EUROW – Sales growth disruption related to COVID-19 influence
EUROW – Sales growth disruption related to COVID-19 influence Q2 2020 • Sales of SEK 15 m, growth of -35% YoY • Antibiotic eluting products growth of -34% • Reduced cost due to adaptations and mitigation of pandemic influence Highlights • Direct sales in the Netherlands from July 1st – Parallel mark
Slide 7: North America – advancing market penetration
North America – advancing market penetration Q2 2020 • Total sales of SEK 22 m, 46% growth vs Q2 2019 • Reduced cost due to adaptations and mitigation of pandemic influence Progressing towards registration of CERAMENT G • De Novo application submitted in April for CERAMENT G in bone infections (oste
Slide 8: Large market opportunity for CERAMENT G in the US
Large market opportunity for CERAMENT G in the US Road to US market for CERAMENT G in two pathways: 1.) De Novo, potential approval by the end of 2020 for bone infections (orange segment in chart below) 2.) PMA (pre-market approval) application based on the results from the large FORTIFY study –to b
Slide 9: Financial Review
Financial Review
Slide 10: Q2 2020 net sales SEK 36.2 m
Q2 2020 net sales SEK 36.2 m -3% Net Sales Q2 10
Slide 11: North America
North America (SEKm) Apr - June 2020 2019 Net Sales 21.6 14.8 +46% Net Sales Gross profit 19.6 13.4 Q2 Contribution -4.2 -23.4 11
Slide 12: EUROW
EUROW (SEKm) Apr - June 2020 2019 Net Sales 14.6 22.5 -35% Net Sales Gross profit 11.7 18.8 Q1 Contribution 2.3 3.8 12
Slide 13: Strong growth in the US despite influence from COVID-19
Strong growth in the US despite influence from COVID-19 Key Figures 2020 2019 2018 SEK m Q2 Q1 Q4 Q3 Q2 (i) Q1 Q4 Q3 Net Sales 36.2 43.4 46.2 39.1 37.3 32.8 23.1 14.2 Gross Margin (%) 86.7 88.7 88.9 87.7 86.5 85.9 85.0 81.8 Operating Loss -23.5 -29.2 -38.6 -32.7 -47.8 -39.0 -45.0 -58.4 Cash at perio
Slide 14: Strong ability to adapt the business
Strong ability to adapt the business Key Figures 2020 2019 2018 SEK m Q2 Q1 Q4 Q3 Q2 (i) Q1 Q4 Q3 Selling expenses (less 23.0 35.0 41.3 33.5 47.9 37.3 37.7 35.1 commissions) Sales Commissions 6.9 7.1 8.0 6.0 4.8 3.5 1.1 - Research and Development 14.0 15.8 18.5 17.4 16.0 16.9 17.6 16.4 expenses Admi
Slide 15: Clear Corporate Strategy Driving Value Creation
Clear Corporate Strategy Driving Value Creation
Slide 16: Strategic execution and situational adoption
Strategic execution and situational adoption Strong progress despite pandemic disruption • Focused distribution strategy driving increased customer base in the US • Advancements to register CERAMENT G on the US market - De Novo application – to accelerate CERAMENT G market entry - PMA application en
Slide 17: CERAMENT Value generating milestones
CERAMENT® Value generating milestones March 2020 Q3 2020 Q4 2020 May 20th Zimmer FDA designated CERAMENT G Q4 2021 Biomet ceases to CERAMENT® G CERAMENT® G CERAMENT G as Australia Launch Potential Market sell CERAMENT “Breakthrough device” approval (De Novo) PMA application 2019 2020 2021 2022 2023
Slide 18: Q&A
Q&A